FDA Drug Enforcement Actions

HEHS-94-136R: Published: May 6, 1994. Publicly Released: May 6, 1994.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

Pursuant to a congressional request, GAO reviewed the Food and Drug Administration's (FDA) monitoring of generic drug manufacturers, focusing on whether: (1) policies and procedures exist to ensure that manufacturers produce safe and effective products; (2) FDA is pursuing enforcement actions against manufacturers; and (3) manufacturing companies are aware of FDA standards for assessing their compliance with good manufacturing practices (GMP). GAO noted that: (1) FDA districts have discretion in dealing with manufacturers and training their investigators; (2) FDA lacks assurance that districts select and inspect manufacturers fairly and that districts forward recommendations for enforcement action to FDA headquarters; (3) FDA is developing certification criteria for drug investigators, since decentralized training does not ensure consistent inspections; (4) despite the potential for inconsistent inspections, there have been no inappropriate FDA inspection and enforcement actions; and (5) manufacturers are generally aware of the standards that FDA uses to determine GMP compliance.

Sep 21, 2016

Aug 3, 2016

Aug 1, 2016

Jul 14, 2016

Jul 5, 2016

Jun 30, 2016

Jun 28, 2016

Jun 23, 2016

Jun 22, 2016

Looking for more? Browse all our products here